Nadeem Moiz, named CEO on October 1, envisions building a unified aesthetics, skincare and therapeutics company grounded in scientific innovation and customer centricity. He emphasizes combining expertise across regenerative medicine, injectables and consumer skin health under the Revance name to serve providers, patients and end consumers more effectively.

Revance’s portfolio includes DAXXIFY, the first peptide-formulated neuromodulator for moderate to severe frown lines, SkinPen microneedling device and the RHA Collection dynamic hyaluronic acid fillers. Its consumer skincare lineup spans acne treatments, sun protection and anti-aging brands such as PanOxyl, Blue Lizard and StriVectin.

DAXXIFY remains in early commercial stages despite its differentiated peptide formulation and U.S. manufacturing. Moiz identifies significant upside in broadening provider adoption and increasing patient awareness to capture share from incumbent neuromodulators.

Key priorities include expanding the sales force, enhancing provider and patient education initiatives and deepening market penetration across the U.S. These efforts aim to accelerate revenue growth and shift industry perceptions toward innovative, science-driven aesthetics solutions.